## William R Tyor

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2711470/publications.pdf

Version: 2024-02-01

136740 123241 3,871 64 32 citations h-index papers

61 g-index 64 64 64 3518 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	240 Neurologic complications in children with seizures and respiratory illness: A comparison between SARS-CoV-2 and other respiratory viruses. Journal of Clinical and Translational Science, 2022, 6, 38-39.	0.3	O
2	CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease. Journal of Investigative Medicine, 2020, 68, 321-330.	0.7	36
3	Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurology, 2020, 77, 480.	4.5	48
4	Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model. Journal of NeuroVirology, 2020, 26, 838-845.	1.0	2
5	Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. Scientific Reports, 2019, 9, 8733.	1.6	14
6	Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. Journal of Neuroinflammation, 2019, 16, 182.	3.1	36
7	Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2019, 25, 673-685.	1.0	42
8	CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. Frontiers in Immunology, 2019, 10, 480.	2.2	91
9	Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance. Clinical Infectious Diseases, 2018, 67, 137-140.	2.9	5
10	A mouse model of HIV-associated neurocognitive disorders: a brain-behavior approach to discover disease mechanisms and novel treatments. Journal of NeuroVirology, 2018, 24, 180-184.	1.0	9
11	Reversing interferon-alpha neurotoxicity in a HIV-associated neurocognitive disorder mouse model. Aids, 2018, 32, 1403-1411.	1.0	13
12	Update on Disease-Modifying Therapies for Multiple Sclerosis. Journal of Investigative Medicine, 2017, 65, 883-891.	0.7	103
13	Peroxisome proliferatorâ€activated receptorâ€Î³ agonists attenuate biofilm formation by <i>Pseudomonas aeruginosa</i> . FASEB Journal, 2017, 31, 3608-3621.	0.2	29
14	In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common Antiretrovirals. Neurochemical Research, 2017, 42, 3220-3232.	1.6	23
15	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. Journal of NeuroVirology, 2017, 23, 106-112.	1.0	22
16	HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?. Journal of the International AIDS Society, 2016, 19, 21008.	1.2	0
17	Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. Journal of NeuroVirology, 2016, 22, 816-822.	1.0	8
18	The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiology of Disease, 2016, 92, 137-143.	2.1	60

#	Article	IF	CITATIONS
19	HIV-associated neurocognitive disorders. Neurology: Clinical Practice, 2015, 5, 224-231.	0.8	37
20	Interferon-α Induces Neurotoxicity Through Activation of the Type I Receptor and the GluN2A Subunit of the NMDA Receptor. Journal of Interferon and Cytokine Research, 2015, 35, 317-324.	0.5	27
21	Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons. Neurochemical Research, 2015, 40, 2220-2229.	1.6	19
22	The Recombinant Vaccinia Virus Gene Product, B18R, Neutralizes Interferon Alpha and Alleviates Histopathological Complications in an HIV Encephalitis Mouse Model. Journal of Interferon and Cytokine Research, 2014, 34, 510-517.	0.5	12
23	Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. Journal of NeuroVirology, 2014, 20, 9-17.	1.0	19
24	Mumps and rubella. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 591-600.	1.0	20
25	Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology, 2013, 10, 61.	0.9	63
26	Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2013, 19, 515-522.	1.0	34
27	Interferon-α (IFNα) neurotoxicity. Cytokine and Growth Factor Reviews, 2012, 23, 7-14.	3.2	43
28	Morphine Exposure During HIV Encephalitis in SCID Mice. Neurochemical Research, 2012, 37, 2836-2841.	1.6	3
29	Regulation of Th $1/Th17$ cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. Journal of Neuroimmunology, 2011, 232, 179-185.	1.1	35
30	Interferon-α Causes Neuronal Dysfunction in Encephalitis. Journal of Neuroscience, 2009, 29, 3948-3955.	1.7	74
31	Intra-peritoneal Injection of Polyclonal Anti-Interferon Alpha Antibodies Cross the Blood Brain Barrier and Neutralize Interferon Alpha. Neurochemical Research, 2008, 33, 2281-2287.	1.6	14
32	HIV-1 Clade-Specific Differences in the Induction of Neuropathogenesis. Journal of Neuroscience, 2008, 28, 10010-10016.	1.7	107
33	Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-α in the brain. Aids, 2007, 21, 2151-2159.	1.0	44
34	Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Experimental Neurology, 2007, 205, 506-512.	2.0	34
35	Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. Journal of Neuroimmunology, 2007, 190, 139-145.	1.1	57
36	Neurosarcoidosis. Current Treatment Options in Neurology, 2007, 9, 161-168.	0.7	22

#	Article	IF	CITATIONS
37	Impact of Opiate–HIV-1 Interactions on Neurotoxic Signaling. Journal of NeuroImmune Pharmacology, 2006, 1, 98-105.	2.1	52
38	Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Annals of Neurology, 2005, 57, 795-803.	2.8	35
39	Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. Journal of Neuroscience Research, 2005, 81, 53-61.	1.3	49
40	Molecular targets of opiate drug abuse in neuro AIDS. Neurotoxicity Research, 2005, 8, 63-80.	1.3	78
41	The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: Deficits in cognitive function. Journal of NeuroVirology, 2004, 10, 109-115.	1.0	27
42	Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet, The, 2004, 363, 1607-1608.	6.3	456
43	Therapeutic options in neurosarcoidosis. Expert Review of Neurotherapeutics, 2002, 2, 703-708.	1.4	0
44	Treatment of spinal cord impact injury in the rat with transforming growth factor- $\hat{l}^2$ . Journal of the Neurological Sciences, 2002, 200, 33-41.	0.3	71
45	Update on viral encephalitis. Current Opinion in Neurology, 2001, 14, 369-374.	1.8	48
46	Neurosarcoidosis. Current Treatment Options in Neurology, 2001, 3, 529-535.	0.7	5
47	Acute multiple sclerosis characterized by extensive mononuclear phagocyte infiltration. Neurochemical Research, 2000, 25, 1517-1520.	1.6	7
48	Interferon beta-1b and childhood multiple sclerosis. Pediatric Neurology, 1999, 21, 481-483.	1.0	40
49	Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex?. Journal of Leukocyte Biology, 1999, 65, 475-481.	1.5	48
50	Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. Brain Research, 1998, 784, 299-304.	1.1	32
51	Long-term intracranial cannula stabilization in mice with light cured resin composites. Journal of Neuroscience Methods, 1998, 79, 31-36.	1.3	19
52	Potential Relationships Between the Presence of HIV, Macrophages, and Astrogliosis in SCID Mice with HIV Encephalitis. Journal of Neuro-AIDS, 1998, 2, 1-20.	0.2	10
53	Transforming Growth Factor- $\hat{l}^21$ in Adult Human Microglia and Its Stimulated Production by Interleukin-1. Journal of Interferon and Cytokine Research, 1997, 17, 655-664.	0.5	12
54	The role of antibody in recovery from alphavirus encephalitis. Immunological Reviews, 1997, 159, 155-161.	2.8	114

#	Article	IF	CITATIONS
55	Cocaine/Sex Type Effects on T Lymphocytes: A Preliminary Report. Drug and Chemical Toxicology, 1996, 19, 109-119.	1.2	2
56	Unifying Hypothesis for the Pathogenesis of HIV-Associated Dementia Complex, Vacuolar Myelopathy, and Sensory Neuropathy. Journal of Acquired Immune Deficiency Syndromes, 1995, 9, 379???388.	0.3	106
57	Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dememtia. Annals of Neurology, 1993, 33, 576-582.	2.8	444
58	Gliosis in human brain: relationship to size but not other properties of astrocytes. Brain Research, 1993, 600, 161-165.	1.1	56
59	Control of astrocytosis by interleukin-1 and transforming growth factor- $\hat{l}^21$ in human brain. Brain Research, 1993, 631, 39-45.	1.1	78
60	Virus specificity and isotype expression of intraparenchymal antibody-secreting cells during Sindbis virus encephalitis in mice. Journal of Neuroimmunology, 1993, 48, 37-44.	1.1	29
61	Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. Journal of Neuroimmunology, 1992, 40, 153-165.	1.1	160
62	Cytokine expression in the brain during the acquired immunodeficiency syndrome. Annals of Neurology, 1992, 31, 349-360.	2.8	596
63	The Characterization of la Expression During Sindbis Virus Encephalitis in Normal and Athymic Nude Mice. Journal of Neuropathology and Experimental Neurology, 1990, 49, 21-30.	0.9	16
64	Macrophage responses in inflammatory demyelinating neuropathies. Annals of Neurology, 1990, 27, S64-S68.	2.8	76